Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study (Q28291971)

2

object named as

Michel Komajda

0 references

Karl Swedberg

1

object named as

Karl Swedberg

0 references

author name string

Michael Böhm

3

0 references

Jeffrey S Borer

4

0 references

Ian Ford

5

0 references

Ariane Dubost-Brama

6

0 references

Guy Lerebours

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

7

0 references

language of work or name

English

0 references

publication date

11 September 2010

0 references

published in

The Lancet

0 references

volume

376

0 references

issue

9744

0 references

page(s)

875-85

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Beta-blockers in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Ventricular remodeling in heart failure and the effect of beta-blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

The myocardium in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

The multifactor primary prevention trial in Göteborg, Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Predictors of mortality and morbidity in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Funny channels in the control of cardiac rhythm and mode of action of selective blockers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

I f inhibition with ivabradine : electrophysiological effects and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961198-1

7 January 2021

10.1016/S0140-6736(10)61198-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20801500

1 reference

Consolidated OpenCitations Corpus – April 2017